INTRODUCTION
============

Parkinson\'s disease (PD) is the second most common progressive neurodegenerative disorder after Alzheimer\'s disease.[@B1] It is characterized by the loss of dopaminergic neurons of the substantia nigra and the presence of intraneuronal cytoplasmic inclusions, known as Lewy bodies, which are aggregates of α-synuclein.[@B1] To detect the loss of dopaminergic neurons in PD, dopamine transporter (DAT) imaging has been employed with single-photon emission computed tomography (SPECT) and positron emission tomography (PET).[@B2] DAT is a sodium chloride-dependent transmembrane protein on the presynaptic dopaminergic nerve terminal, and controls dopamine levels by active reuptake from the synaptic cleft.[@B3][@B4][@B5] DAT imaging allows quantifying of the dopaminergic system in the human brain[@B6] and *in vivo* demonstration of striatal dopamine activity.[@B5] As ^123^I-FP-CIT shows a higher affinity for striatal DAT density,[@B3] it is one of the most widely used radiotracers in evaluating neurodegenerative disease.[@B7][@B8]

α-synuclein, a small, natively unfolded protein in presynaptic axon terminals[@B9][@B10][@B11] plays a role in regulation of dopamine biosynthesis and terminating dopamine neurotransmission by altering DAT-mediated uptake of synaptic dopamine.[@B12][@B13] Aggregates of α-synuclein protein are a neuropathological hall-mark of PD.[@B14][@B15] Many previous efforts have attempted to determine the usefulness of α-synuclein in cerebrospinal fluid (CSF), synuclein gene (*SNCA*), and single nucleotide polymorphisms (SNPs) as biomarkers for PD. Mean CSF α-synuclein levels are significantly lower in patients with typical PD, and may be a biomarker for PD diagnosis.[@B16]

*SNCA* is selectively expressed in blood cells and neurons.[@B10][@B17] Previous studies have evaluated alternative *SNCA* transcripts from blood as specific biomarkers for PD development. However, until now, the roles of *SNCA* transcripts are not well understood. Previous studies have reported a positive correlation between DAT imaging and *SNCA* transcripts in PD.[@B18][@B19] In the Parkinson\'s Progression Markers Initiative (PPMI), five *SNCA* transcripts, transcript with boundaries of exon 3 and exon 4 (SNCA-E3E4), transcripts with a long 3′UTR region (SNCA-3UTR-1, SNCA-3UTR-2), transcripts that skip exon 5 (SNCA-E4E6), and rare short transcript isoforms that comprise exons 1--4 (SNCA-007), were counted to evaluate their ability as specific biomarkers for PD. In genome-wide association study, several SNPs in *SNCA* were associated with PD.[@B20] However, the effect of SNP in *SNCA* was not investigated.

In this regard, we hypothesized that α-synuclein levels in CSF, *SNCA*, and SNP of *SNCA* might have an effect on DAT availability in healthy subjects. Therefore, we investigated the association between DAT availability measured from ^123^I-FP-CIT SPECT and α-synuclein levels in CSF, as well as *SNCA* transcripts from venous blood, and the effect of SNP of *SNCA* on DAT availability in healthy subjects using the PPMI database.

MATERIALS AND METHODS
=====================

Subjects
--------

Data used in the preparation of this article were obtained from the PPMI database ([www.ppmi-info.org/data](www.ppmi-info.org/data)). For up-to-date information on the study, visit [www.ppmi-info.org](www.ppmi-info.org).[@B21] The study population consisted of healthy controls who underwent ^123^IFP-CIT SPECT screening. According to PPMI criteria of healthy subjects, males or females with an age of 30 years or older at screening were included, and subjects with a neurological disorder, a first degree relative with idiopathic PD, Montreal Cognitive Assessment score of 26 or less, medications that might interfere with DAT SPECT scans, anticoagulants that might preclude safe completion of the lumbar puncture, or investigational drugs, and a condition that precludes the safe performance of routine lumbar puncture were excluded. Subjects without CSF α-synuclein, RNA synuclein, and genotyping were excluded. Medical history, CSF, RNA synuclein counts, and ^123^I-FP-CIT SPECT scans were downloaded. The PPMI study was approved by the local Institutional Review Boards of all participating sites (Institute for Neurodegenerative Disorders, University of Pennsylvania, University of California, Los Angeles, Coriell Institute for Medical Research, Clinical Trials Coordination Center, Laboratory of Neurogenetics; National Institute on Aging NIH, Institute for Neurodegenerative Disorders, Clinical Trials Statistical and Data Management Center, University of Iowa), and written informed consent was obtained from each subject at the time of enrollment for imaging data and clinical questionnaires. All methods were performed in accordance with the relevant guidelines and regulations.

^123^I-FP-CIT SPECT and image analysis
--------------------------------------

^123^I-FP-CIT SPECT was performed during the screening visit for all subjects. SPECT scans were acquired 4±0.5 hrs after injection of 111--185 MBq of ^123^I-FP-CIT. Subjects were pretreated with iodine solution or perchlorate prior to injection to block thyroid uptake. Raw data were acquired into a 128×128 matrix stepping every 3 or 4 degrees for the total projections. Raw projection data were reconstructed using iterative ordered subset expectation maximization with HERMES (Hermes Medical Solutions, Stockholm, Sweden). The reconstructed images were transferred to pmod (PMOD Technologies LLC, Zürich, Switzerland) for subsequent processing, including attenuation correction.

Downloaded scans were loaded using pmod v3.6 (PMOD Technologies LLC) with a ^123^I-FP-CIT template.[@B22] Specific binding of ^123^I-FP-CIT regarding DAT was calculated using a region of interest analysis. A standard set of volumes of interest (VOIs) defining the caudate nucleus and putamen based on the Automated Anatomical Labeling (AAL) atlas[@B23] was defined. The cerebellum was chosen as a reference region. VOI template was applied to measure specific binding ratios (SBRs) of the caudate nucleus, putamen, and striatum as follows: SBR=(target-cerebellum)/cerebellum. As semi-automatic software (pmod v3.6, PMOD Technologies LLC) with predefined AAL atlas was used to analyze SPECT scans, inter- and intra-observer variation might be negligible.

Synuclein
---------

α-synuclein in CSF was analyzed using an enzyme-linked immunosorbent assay (Covance Research Products Inc., Denver, PA, USA) according to the manufacturer\'s instructions. Samples were run in duplicate, and data used for this study met quality control measures for technical performance. Venous blood was collected from each subject in PAXgene tubes (Qiagen, Valencia, CA, USA), incubated at room temperature for 24 hours, and frozen and shipped on dry ice to Coriell. RNA was extracted following the PAXgene procedure. Probes for the target and control RNAs were multiplexed and assayed on the nCounter Digital Analyzer (NanoString Technologies, Inc.). Five *SNCA* probes were used to target the boundaries of exon 3 and exon 4 (SNCA-E3E4), transcripts with a long 3′UTR region (SNCA-3UTR-1, SNCA-3UTR-2), transcripts that skip exon 5 (SNCA-E4E6), and the rare short transcript isoforms that comprise exons 1--4 (SNCA-007). Transcript counts were assayed in human blood in a high-precision NanoString gene expression assay that directly measures RNA counts in total RNA without bias from reverse transcription into cDNA. No template controls containing water substituted for template were included. To control for plate-to-plate variation and drift, equal amounts of RNA derived from Human Universal Reference RNA (Agilent Technologies) were spotted at the beginning, end, and throughout the entire experiment.

Genotyping-rs3910105
--------------------

All samples were genotyped using Illumina NeuroX array following the manufacturer\'s protocol (Illumina, Inc., San Diego, CA, USA). The Genotyping Analysis Module within Genome Studio version 1.9.4 was used to analyze data. The genotype frequencies for SNPs were in Hardy-Weinberg Equilibrium (\>0.05), and minor allele frequency was more than 0.05.

Statistical analysis
--------------------

Normality was examined using D\'Agostino-Pearson omnibus test. Kruskal-Wallis test was used to compare three subgroups of SNPs. Post-hoc analysis was done to compare two subgroups of SNPs using Mann-Whitney test. Spearman correlation was used to investigate the relationship between DAT availability and synuclein. Statistical analyses were performed using GraphPad Prism 7 for Mac OS X (GraphPad Software Inc., San Diego, CA, USA), and MedCalc software package (ver. 12.6.0.0, MedCalc, Mariakerke, Belgium).

RESULTS
=======

Subject characteristics according to rs3910105
----------------------------------------------

In total, 123 healthy subjects (male 75, female 48) were included in this study. rs3910105 was in Hardy-Weinberg Equilibrium, and the minor allele frequency was 0.47. According to genotyping of rs3910105, 30 subjects were of CC genotype, 57 of CT, and 36 of TT. rs3910105 did not show any effect on CSF α-synuclein (*p*=0.8026), and RNA synuclein (SNCA-007, *p*=0.1137; SNCA-3UTR-1, *p*=0.8894; SNCA-3UTR-2, *p*=0.7179; SNCA-E3E4, *p*=0.2826; SNCA-E4E6, *p*=0.4110) ([Table 1](#T1){ref-type="table"}). However, DAT availability in the caudate nucleus (*p*=0.0661) and putamen (*p*=0.0739) tended to differ according to rs3910105 genotype. In post-hoc analysis, DAT availability in the putamen was lower in subjects of TT genotype than those of CC/CT (*p*=0.0317). DAT availability in the caudate nucleus tended to be similar with that in the putamen (*p*=0.0597) ([Fig. 1](#F1){ref-type="fig"}).

Correlation between DAT availability and synuclein
--------------------------------------------------

The correlation between DAT availability and synuclein was not significant in 123 subjects. However, after dividing subjects into 3 groups according to rs3910105, those with CT genotype of rs3910105 showed negative correlations of DAT availabilities of putamen with SNCA-E3E4 (*p*=0.037, rho=−0.277), and SNCA-E4E6 (*p*=0.042, rho=−0.270) ([Fig. 2](#F2){ref-type="fig"}). In addition, SNCA-3UTR-1 (*p*=0.084, rho=−0.231), and SNCA-3UTR-2 (*p*=0.091, rho=−0.226) also showed the trend toward negative correlation with DAT availability of putamen in those with CT genotype ([Table 2](#T2){ref-type="table"}). However, in subjects with CC and TT genotypes did not show the meaningful association between DAT availability and synuclein.

DISCUSSION
==========

In this study, rs3910105 appeared to effect DAT availability in the striatum. In subjects with CT genotype, higher DAT availability in the striatum and significant correlations with *SNCA* transcripts (SNCA-E3E4, SNCA-E4E6) were noted.

rs3910105, a SNP of *SNCA*, is a significant predictor of change in β-amyloid 1--42 (Aβ42), which has been shown to be relevant in PD neurodegeneration.[@B24] However, rs3910105 shows a relatively subtle association with temporal Lewy body counts in the brain, and it seems to play a limited role in the degree to which Lewy body pathology progresses.[@B25] Additionally, rs3910105 was not shown to be associated with cognitive decline in untreated PD patients.[@B26] Still, the role of rs3910105 in PD, as well as healthy subjects, has remained unclear. In this study, *SNCA* transcripts showed a significant correlation with DAT availability in subjects of CT genotype, not in those of CC or TT. Until now, as this is the first study to report the effect of rs3910105 and a correlation between *SNCA* transcripts and DAT availability, the underlying mechanism of this association is not clear.

Previous studies have reported the effects of genotypes on DAT availabilities. CC genotypes with rs5443 of the G-protein β3 subunit gene showed higher DAT availability measured by ^99m^Tc-TRODAT-1 SPECT than other genotypes.[@B27] The effect of a variable number tandem repeat of SLC6A3 on DAT availability is well-known.[@B28][@B29] In addition, the effect of rs53576 of oxytocin receptor gene was also reported, and genetic variation in the common downstream signaling molecule of dopamine autoreceptors may affect the dysregulation of the striatal dopamine system.[@B27][@B30] As aggregations of α-synuclein are considered to be a central factor in the development of Lewy bodies in PD[@B1][@B19] and as the expressions of *SNCA* transcripts in healthy subjects were higher than those in PD,[@B31] we hypothesized that *SNCA* transcripts are correlated positively with DAT availability. However, contrary to our expectations, the correlation between *SNCA* transcripts and DAT availability was significant, although negatively in subjects with CT genotype of rs3910105. α-synuclein consists of three domains with a N-terminal lipidbinding α-helix, amyloid-binding central domain, and C-terminal acidic tail,[@B32][@B33] which has a function in suppression of apoptosis, regulation of glucose, modulation of calmodulin activity, chaperone activity, and regulation of dopamine biosynthesis.[@B32] Although the role of the majority of *SNCA* transcripts remains unknown, SNCA-3UTR is associated with the accumulation of long transcripts;[@B34] SNCA-E4E6 leads to shortening of α-synuclein C-terminal.[@B17] In addition, reduced *SNCA* transcripts, especially SNCA-3UTR and SNCA-E4E6, might have a clinical role as potential predictors of cognitive decline in PD.[@B31] In addition, Gao, et al.[@B18] reported a positive correlation between *SNCA* transcripts and cerebral vesicular monoamine transporter 2 binding measured from ^18^F-AV133 PET in PD. However, 8 patients were included in this study, and PD patients were not categorized according to genotypes of SNP of *SNCA*.

This is the first study to report the effect of rs3910105 on DAT availability in the striatum and correlations between *SNCA* transcripts and DAT availability. However, there are several limitations in this study. Until now, as there are no previous studies regarding rs3910105 and *SNCA* transcripts, we could not explain the underlying mechanisms of this phenomenon. Secondly, although we included as many as 133 healthy subjects, we could not evaluate the reproducibility of our results using other databases. Further studies with a prospective design and basic research might be needed to clarify the association between *SNCA* transcripts and DAT availability.

In conclusion, this is the first study to investigate the association of rs3910105 of *SNCA* with DAT availability measured from ^123^I-FP-CIT SPECT. rs3910105 had an effect on DAT availability, and the correlation between DAT availability and *SNCA* transcripts were significant in CT genotypes of rs3910105.
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###### Subject Characteristics according to Genotype of rs3910105

![](ymj-59-787-i001)

  Variables                 rs3910105        *p* value                         
  ------------------------- ---------------- ---------------- ---------------- --------
  Age (yrs)                 62.8±11.9        57.6±12.2        63.0±10.9        0.1262
  Sex (male/female)         17/13            34/23            24/12            0.6817
  BMI (kg/m^2^)             26.5±4.2         27.3±4.6         25.9±3.5         0.1878
  CSF α-synuclein (pg/mL)   2181.3±910.9     2100.1±1014.0    2083.8±942.3     0.8026
  RNA synuclein (counts)                                                       
   SNCA-007                 16.8±9.0         21.9±14.3        24.2±14.2        0.1137
   SNCA-3UTR-1              1998.3±1008.9    2049.6±1328.1    2113.1±1194.6    0.8894
   SNCA-3UTR-2              596.6±301.7      614.5±396.1      652.3±378.6      0.7179
   SNCA-E3E4                11730.7±5378.6   13315.3±6622.7   14822.4±7104.2   0.2826
   SNCA-E4E6                2583.3±1211.6    2947.8±1513.7    3235.4±1722.7    0.4110
  DAT availability                                                             
   Caudate nucleus          1.6±0.4          1.7±0.4          1.6±0.4          0.0661
   Putamen                  2.1±0.4          2.1±0.4          1.9±0.3          0.0739

BMI, body mass index; CSF, cerebrospinal fluid; *SNCA*, synuclein gene; DAT, dopamine transporter.

###### Correlation Coefficient (rho) between Dopamine Transporter Availability and Synuclein in Subjects according to Genotype of rs3910105

![](ymj-59-787-i002)

                            rs3910105                                             
  ------------------------- ----------- -------- -------- ------------ ---------- -------
  CSF α-synuclein (pg/mL)   0.168       0.127    0.076    0.140        0.177      0.045
  RNA synuclein (counts)                                                          
   SNCA-007                 −0.031      −0.233   −0.108   −0.153       0.291^†^   0.198
   SNCA-3UTR-1              0.034       0.007    −0.179   −0.231^†^    0.112      0.045
   SNCA-3UTR-2              0.080       0.111    −0.198   −0.226^†^    0.053      0.007
   SNCA-E3E4                −0.096      −0.068   −0.205   −0.277^\*^   0.264      0.102
   SNCA-E4E6                −0.019      −0.016   −0.201   −0.270^\*^   0.275      0.115

CSF, cerebrospinal fluid; *SNCA*, synuclein gene.

^\*^*p*\<0.05, ^†^*p*\<0.1.
